Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LXP1788 in Advanced Solid Tumors
NCT06883539Phase 1Recruiting
- Sponsor
- LaunXP Biomedical Co., Ltd.
- Start
- Dec 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DBPR114 in solid tumor (advanced stage), hepatocellular carcinoma (HCC), renal cell carcinoma (RCC) and 1 more, sponsored by LaunXP Biomedical Co., Ltd. Primary endpoints: Maximum Tolerated Dose at 2 years, Recommended Phase 2 Dose at 2 years and 1 more. Started Dec 2024; status: recruiting.
02
Drugs
DBPR114
03
Conditions
solid tumor (advanced stage)hepatocellular carcinoma (HCC)renal cell carcinoma (RCC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06883539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06883539.